

Adult CIRB - Late Phase Emphasis Meeting Agenda

March 20, 2025

I. Initial Review

A032302, Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE) (Version Date 02/07/25)

II. Initial Review

NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) (Version Date 02/21/25)

III. Amendment

S2207, Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma (Version Date 01/24/25)

IV. Continuing Review

A041702, A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (\geq 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (Version Date 01/07/25)

V. Continuing Review

A072201, Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma (Version Date 08/22/24)

VI. Continuing Review

NRG-HN010, A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers (Version Date 12/05/24)

VII. Continuing Review

NRG-LU002, Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial (Version Date 10/18/23)

VIII. Continuing Review

EA5181, Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (Version Date 05/28/24)
